{
    "Clinical Trial ID": "NCT00795769",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ondansetron Therapy",
        "  Patients receive 16mg ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.",
        "  ondansetron: Given IV",
        "  survey administration: Correlative studies",
        "  management of therapy complications: Ondansetron IV"
    ],
    "Eligibility": [
        "Inclusion",
        "  Autologous PBSC transplant patient",
        "  English-speaking",
        "  Planned cryopreserved PBSC infusion at the SCCA outpatient clinic",
        "  Exclusion",
        "  History of prior autologous transplant",
        "  Non-English-speaking",
        "  Planned cryopreserved PBSC infusion at the UWMC inpatient unit",
        "  Infusion of cryopreserved PBSC that are thawed and washed to remove DMSO prior to infusion",
        "  Allergy or adverse reaction to ondansetron"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates)",
        "  Nausea Multinational Association of Supportive Care in Cancer Antiemesis Tool\u2122 (MAT). Increased MAT scores represent worse outcome (score 0-10). Vomiting represented as present or absent.",
        "  Time frame: Baseline up to 120 minutes",
        "Results 1: ",
        "  Arm/Group Title: Ondansetron Therapy",
        "  Arm/Group Description: Patients receive 16mg ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.",
        "  ondansetron: Given IV",
        "  survey administration: Correlative studies",
        "  management of therapy complications: Ondansetron IV",
        "  Overall Number of Participants Analyzed: 49",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  MAT score >2 on arrival and pre-ondansetron: 23  46.9%",
        "  Baseline MAT score >2 prior to first ASCT infusion: 9  18.4%",
        "  MAT score increases >2 by end of infusion: 12  24.5%",
        "  Number of patients that vomited: 9  18.4%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/49 (0.00%)"
    ]
}